|
COPYRIGHT 2005 PR Newswire Association LLC
LYON, France, Oct. 31 /PRNewswire/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group , has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be tested by sanofi pasteur to determine its ability to enhance the immune response to a broad range of vaccines.
Under the terms of the agreement, Eisai will provide a license to sanofi...
Read the full article for free courtesy of your local library.
|